Top Markets
Coin of the day
Apexigen, Inc. Apexigen, Inc.

Apexigen, Inc.

APGN
Rankning i aktier #36265
Apexigen Inc., established in 2010 and based in San Carlos, California, is a... Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.
Aktiekurs
$0.385
Senast synkroniserad: 2023-09-01
Marknadsvärde
$2.86M
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Apexigen, Inc. (APGN)

Kategori

EPS för Apexigen, Inc. (APGN)
EPS per 2026 TTM: 0
Enligt Apexigen, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Apexigen, Inc. från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter